Allurion Technologies Inc

Allurion Technologies Inc

Allurion Technologies is a medical-device company focused on non-surgical weight-loss solutions, most notably a swallowable gastric balloon and a digital programme to support patient weight management. The company operates in the obesity-treatment segment, combining a device with remote monitoring and clinical services. For investors this is a micro-cap idea: market capitalisation is small and liquidity can be limited, which tends to increase share-price volatility and execution risk. Potential attractions include exposure to a growing global demand for less-invasive obesity therapies and the possibility of scaling via clinic partnerships, tech-enabled follow-up and new markets. Key risks include regulatory and clinical outcomes, competition from established device makers and drug therapies, uncertain revenue visibility and the potential need for additional financing. This summary provides general educational information only and is not personal advice. Values can rise and fall; investors should assess company filings, clinical data and market dynamics, and consider suitability for their own risk tolerance.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts suggest buying Allurion Technologies' stock, with a target price of $37.13, indicating strong potential.

Above Average

Financial Health

Allurion Technologies is performing well with strong revenue, profit margins, and cash flow.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring ALUR

The Global Weight-Loss Drug Price Shift

The Global Weight-Loss Drug Price Shift

Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.

Published: August 15, 2025

Explore Basket
Executive Conviction In The GLP-1 Market

Executive Conviction In The GLP-1 Market

Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.

Published: August 13, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Market opportunity

Obesity treatment is a growing global market and less-invasive options attract interest; however, adoption can be gradual and revenue growth is not guaranteed.

Device plus software

Combining a physical device with remote monitoring and digital care can create differentiated services, though clinical outcomes and reimbursement matter for uptake.

🌍

Scale and risks

International clinic partnerships offer expansion potential, but small market cap and regulatory hurdles mean execution and financing risks are material.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions